Retatrutide (LY-3437943) is an investigational triple-agonist peptide developed by Eli Lilly for the treatment of obesity and metabolic diseases.
It activates three key metabolic receptors simultaneously:
GLP-1 (Glucagon-like Peptide-1)
GIP (Glucose-dependent Insulinotropic Polypeptide)
GCGR (Glucagon Receptor)
This triple agonism amplifies metabolic signalling and has demonstrated powerful effects on weight reduction, glucose regulation, and fat-mass reduction.
Retatrutide is currently in Phase 3 clinical trials, making it one of the most advanced next-generation GLP-1–based therapeutics in development.
